Resverlogix Corp. (TSX: RVX)
Health Care · Biotechnology · CA
CA$0.08
-5.88% today · -23.8% 1Y
Resverlogix Corp. (TSX: RVX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $19.47M and employs 17 people.
Over the last twelve months the share price has lost 23.8%, trading between 0.08 and 0.15.
Tweenvest scores Resverlogix Corp. across four factors: quality 11/100, value 74/100. Its strongest factor is value.
RVX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $19.47M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 1.06
- 52-week high
- CA$0.15
- 52-week low
- CA$0.08
- Avg volume (3M)
- —
- Shares outstanding
- 344.29M
- Employees
- 17
- Next earnings
- —
About Resverlogix Corp.
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
- ISIN
- CA76128M1086
- Listed since
- May 7, 2004
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MDxHealth SANasdaqCM: MDXH | $19.71M | $0.21 | -64.97% |
| Modalis Therapeutics CorporationTSE: 4883 | $19.56M | ¥29.00 | -3.33% |
| Elicera Therapeutics AB (publ)OM: ELIC | $19.51M | Skr2.90 | +5.08% |
| Nexsen LimitedASX: NXN | $19.50M | AU$0.14 | +7.69% |
| Inhibitor Therapeutics, Inc.OTCPK: INTI | $19.10M | $0.11 | +12.14% |
| GenSight Biologics S.A.ENXTPA: SIGHT | $19.05M | €0.07 | -5.00% |
| HST Global, Inc.OTCPK: HSTC | $18.91M | $0.13 | -80.90% |
| Dextech Medical ABXSAT: DEX | $18.89M | Skr— | — |
Figures last refreshed Oct 18, 2026.